Advertisement

Topics

Two interesting data sets at #ECTRIMS2018 $MRK.DE BTKi Evobrutinib looks competitive vs $BIIB Tecfidera in MS https://twitter.com/DrKantor/status/1050732895525097473 … $RHHBY anti-IL6 Satralizumab efficacy on par with $ALXN Soliris in AQP4+ NMO with

11:07 EDT 12 Oct 2018 | Andy Biotech

Two interesting data sets at BTKi Evobrutinib looks competitive vs Tecfidera in MS https://twitter.com/DrKantor/status/1050732895525097473 … anti-IL6 Satralizumab efficacy on par with Soliris in AQP4+ NMO with dosing advantage (Q4W SubQ vs. Q2W IV) https://twitter.com/DrKantor/status/1050735400711593984 …

Original Article: Two interesting data sets at #ECTRIMS2018 $MRK.DE BTKi Evobrutinib looks competitive vs $BIIB Tecfidera in MS https://twitter.com/DrKantor/status/1050732895525097473 … $RHHBY anti-IL6 Satralizumab efficacy on par with $ALXN Soliris in AQP4+ NMO with

NEXT ARTICLE

More From BioPortfolio on "Two interesting data sets at #ECTRIMS2018 $MRK.DE BTKi Evobrutinib looks competitive vs $BIIB Tecfidera in MS https://twitter.com/DrKantor/status/1050732895525097473 … $RHHBY anti-IL6 Satralizumab efficacy on par with $ALXN Soliris in AQP4+ NMO with"

Advertisement
Quick Search
Advertisement
Advertisement